Because the airway epithelia of CF patients are exposed to the combination of all these inflammatory factors, the use of SMM is a superior approach vs. the use of single inflammatory factors for testing the efficacy of small molecule inhibitors of IRE1α as anti-inflammatory therapeutics. The gene discussed is ERN1; the disease is cystic fibrosis.